 |
|
|
|
|
Prostate Cancer Vaccine Looks Promising in Early Trial
Could help men with metastatic, recurring disease, researchers say
By Steven Reinberg
HealthDay Reporter
|
| | | | Related Healthscout Videos | |
|
SUNDAY, May 18 (HealthDay News) -- A therapeutic vaccine to treat prostate cancer appears safe and may be effective, according to the results of an early trial.
The vaccine could give hope to men with metastatic prostate cancer by activating their immune systems to fight the disease. The vaccine was developed to enable a patient's immune system to produce anti-antigens and attack cancer cells, which can improve quality of life and extend survival.
Text Continues Below
"The primary objective of the study was to determine whether or not the vaccine was safe or whether it induced any serious adverse events," said lead researcher Dr. David Lubaroff, director of urology research at the University of Iowa. "The vaccine was quite safe."
In addition, the researchers wanted to see if the vaccine produced an immune response to prostate specific antigen (PSA).
"We found that 68 to 70 percent of the patients in the trial demonstrated immune responses to PSA," Lubaroff said. "This was their last resort, and we were encouraged by the fact that we could detect any immune response in these patients."
Results of the phase 1 trial were expected to be presented Sunday at the American Urological Association annual meeting, in Orlando, Fla.
In the trial, Lubaroff's team tested the adenovirus/PSA vaccine in 32 men with metastatic prostate cancer. The men were treated with one of three different doses of the vaccine and followed for 12 months.
In addition to developing immune responses to PSA, 57 percent of the patients survived longer than predicted. Forty-eight percent actually doubled their expected life span. The longest survival was almost six years, the researchers reported.
Based on these results, Lubaroff's group has started a phase II trial, which will determine whether the immune response and survival seen in this trial is really therapeutically meaningful in a larger number of patients.
Page: 1 | 2 | Next >>
|
Copyright © 2008 ScoutNews, LLC. All rights reserved.
Last updated 5/18/2008
|
|
SOURCES: David Lubaroff, M.D., director, Urology Research, and professor, urology and microbiology, University of Iowa, Iowa City; Bruce Roth, M.D., professor, medicine and urology, Vanderbilt University, Nashville, Tenn.; May 18, 2008, presentation, American Urological Association annual meeting, Orlando
|
.gif)
